Previous 10 | Next 10 |
2023-05-04 10:04:37 ET XORTX Therapeutics ( NASDAQ: XRTX ) announced a positive outcome of their recent Type D meeting with the U.S. Food and Drug Administration regarding the accelerated approval of XORLO as a treatment for autosomal dominant polycystic kidney disease ((ADPKD). T...
CALGARY, Alberta, May 04, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive ...
2023-04-21 07:25:44 ET The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Xortx Therapeutics' ( NASDAQ: XRTX ) Xorlo (oxypurinol) to treat autosomal dominant polycystic kidney disease (ADPKD). Polycystic kidney disease is an inherited disord...
CALGARY, Alberta, April 21, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disea...
● Type D Meeting Requested to Accelerate XRx-008 Clinical Program ● CALGARY, Alberta, March 14, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company ...
CALGARY, Alberta, Feb. 07, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney diseas...
Xortx Therapeutics ( NASDAQ: XRTX ) said it submitted an orphan drug designation (ODD) request to the U.S. Food and Drug Administration (FDA) for XRx-008 program to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD). The FDA grants orphan drug status to therapies which treat o...
CALGARY, Alberta, Feb. 01, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney diseas...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips There’s great news circulating about Xortx Therapeutics (NASDAQ: XRTX ) today. In a clinical study, XORLO, Xortx’s orally administered brand of oxypurinol, demonstrated a “substantial increase” ...
Xortx Therapeutics ( OTCQB:XRTXF ) ( NASDAQ: XRTX ) reported data from a bridging pharmacokinetics trial of its proprietary formulation of oral oxypurinol, Xorlo, being explored for kidney disease. The company said data from the study, dubbed XRX-OXY-101, showed that Xorl...
News, Short Squeeze, Breakout and More Instantly...
XORTX Therapeutics Inc. Company Name:
XRTX Stock Symbol:
NASDAQ Market:
XORTX Therapeutics Inc. Website:
CALGARY, June 04, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to anno...
CALGARY, Alberta, May 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive ...